Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Minoxidil is a small molecule antihypertensive and vasodilator used for the treatment of resistant hypertension and androgenetic alopecia (pattern hair loss). It was originally developed in the 1970s as a potent peripheral vasodilator. For hypertension, it acts by relaxing arterial smooth muscle, reducing peripheral vascular resistance and lowering blood pressure. The antihypertensive effect is primarily due to its active metabolite, minoxidil sulfate. For hair loss, topical minoxidil prolongs the anagen (growth) phase of hair follicles and may promote survival of dermal papilla cells via activation of extracellular signal-regulated kinase (ERK) and Akt pathways; however, its precise mechanism for stimulating hair growth remains incompletely understood[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on minoxidil.